Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5910566 | 0.84 | MCHR1 (0.50) | KMT2AMEN1 | |
| SCHEMBL6559873 | 0.83 | KMT2A (0.43) | KMT2AMEN1ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL6848360 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5911053 | 0.81 | TP53 (0.43) | KMT2AMEN1ALDH1A1MAPTHTT | |
| SCHEMBL5873486 | 0.79 | KDM4E (0.54) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5909911 | 0.79 | MEN1 (0.56) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6605377 | 0.77 | ALDH1A1 (0.48) | KMT2AALDH1A1MAPTSMN1; SMN2HTT | |
| SCHEMBL5910860 | 0.74 | CHRNB2 (0.50) | KMT2AMEN1ALDH1A1MAPTHTT | |
| SCHEMBL9828594 | 0.74 | TP53BP1 (0.45) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9830188 | 0.73 | CASP3 (0.42) | ALDH1A1HTTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | KMT2A 310/4885MEN1 509/4885ALDH1A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.